Regen BioPharma, Inc.
RGBP
$0.00
$0.000.00%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 59.10K | 59.10K | 59.10K | 59.40K | 59.10K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 59.10K | 59.10K | 59.10K | 59.40K | 59.10K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 59.10K | 59.10K | 59.10K | 59.40K | 59.10K |
| SG&A Expenses | 34.50K | 210.60K | 400.70K | 170.70K | 99.80K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 34.50K | 212.80K | 610.70K | 182.40K | 99.80K |
| Operating Income | 24.50K | -153.70K | -551.60K | -123.10K | -40.80K |
| Income Before Tax | -637.80K | 991.90K | -967.90K | -572.50K | -167.30K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -637.80K | 991.90K | -967.90K | -572.50K | -167.30K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -637.80K | 991.90K | -967.90K | -572.50K | -167.30K |
| EBIT | 24.50K | -153.70K | -551.60K | -123.10K | -40.80K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 0.00 | 0.01 | -0.01 | -0.02 | -0.01 |
| Normalized Basic EPS | 0.00 | 0.00 | -0.01 | -0.01 | 0.00 |
| EPS Diluted | 0.00 | 0.01 | -0.01 | -0.02 | -0.01 |
| Normalized Diluted EPS | 0.00 | 0.00 | -0.01 | -0.01 | 0.00 |
| Average Basic Shares Outstanding | 615.56M | 184.94M | 99.61M | 33.02M | 23.75M |
| Average Diluted Shares Outstanding | 615.56M | 184.94M | 99.61M | 33.02M | 23.75M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |